Virginia A. Schad, PharmD, RPh

A review of 21 studies evaluated the long-term outcomes associated with pulmonary rehabilitation for patients with pulmonary fibrosis, including ILD.

Can an EHR-based sepsis early warning system involving pharmacists and providers improve antibiotic administration in the ED and sepsis-related outcomes?

Can peripheral oxygen saturation levels be used instead of arterial blood gas analysis to calculate SOFA scores in patients with suspected sepsis?

In field-based studies, coaching those who administer spirometry tests may help reduce test failure rates among certain populations.

Because oxidative stress and elevated ASK1 activity appear to play a role in vascular remodeling in PAH, ASK1 inhibition with selonsertib was studied.

Researchers conducted subgroup analysis of revenfenacin phase 3 trial data to assess health status improvements in women vs men with moderate to severe COPD.

A post-hoc analysis compared lung function changes in the INCREASE and TRIUMPH trials of inhaled treprostinil for PH-ILD and PAH.

A clinical trial disproved the notion that adding cyclophosphamide pulses to glucocorticoids was effective for acute exacerbation of IPF.

Clinical trial results indicate that ciclesonide inhalation may be an effective early antiviral therapy for mild to moderate COVID-19.

Researchers analyzed small RNA sequencing in bronchial biopsies to determine the miRNAs involved in asthma pathogenesis.

In non-small cell lung cancer, LncRNA DLGAP1-AS2 regulates miR-503/cyclin D1 to promote cell proliferation.

Researchers examining COVID-19 data from a 13-month period found variations in US usage of dexamethasone, remdesivir, and hydroxychloroquine.

Do gastroprotective and promotility agents prevent incident interstitial lung disease in patients with systemic sclerosis?

What kinds of patients overuse short-acting β2-agonists, and what kinds of health outcomes are associated with these patients?

An NIH review explored whether Bruton tyrosine kinase inhibitors decreased oxygen requirements and hospitalizations for patients with SARS-CoV-2.

Which COPD initial maintenance therapy was associated with better adherence by patients and lower COPD-related medical costs?

Elemental differences detected in blood and baby teeth between children with and without asthma may have implications for the pathogenesis of this prevalent disease.

Increasing evidence suggests that genetic polymorphisms play an important role in COPD development.

Researchers sought to delineate the role of cystic fibrosis transmembrane conductance regulator (CFTR) in pulmonary arterial hypertension pathogenesis through observational and interventional experiments in human tissues and animal models.

NIV is sometimes used in the management of refractory pediatric status asthmaticus, but its effectiveness in pediatric asthma is unproven.

Researchers evaluated the effectiveness of a short multicomponent breathing exercise program for adults aged 65 years or older with persistent asthma.

Does Serum miRNA expression correlate with clinical characteristics of asthma and systemic inflammation in older populations?

Researchers sought to create an updated definition of extensively drug-resistant tuberculosis (XDR-TB).

Metformin has demonstrated potential for slowing emphysema progression and its systemic consequences.

In patients with COPD, an enhanced pulmonary rehabilitation program that emphasizes chronic disease self-management may help to reduce physician visits.

In Norway, the likelihood of a patient experiencing a hospital emergency visit leading to a lung cancer diagnosis increased with older age, more advanced stage, and more comorbidities

Mandatory preprocedurual COVID-19 testing for asymptomatic patients does not necessarily decrease rates of infection among health care workers.

Patients who have severe eosinophilic asthma that is uncontrolled on omalizumab may be effectively switched to mepolizumab.

Enrollment in high-deductible health plans may not be associated with changes in asthma medication use or exacerbations when medications are exempt from the deductible.

Lumacaftor-ivacaftor is generally safe and well tolerated for long-term treatment of children with cystic fibrosis homozygous for the F508del-CFTR mutation.